Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 19/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.52 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Inogatran SCHEMBL22746 | 1.00 | F2 (0.52) | F2PRSS1F10PLGPLAT | |
| Inogatran SCHEMBL1208039 | 1.00 | F2 (0.52) | F2PRSS1F10PLGPLAT | |
| Inogatran SCHEMBL6666022 | 0.99 | F2 (0.51) | F2PRSS1F10PLGPLAT | |
| SCHEMBL8409263 | 0.87 | F2 (0.45) | F2PRSS1F10PLGPLAT | |
| Inogatran SCHEMBL871973 | 0.87 | F2 (0.47) | F2PRSS1F10PLGPLAT | |
| SCHEMBL6665350 | 0.84 | PRCP (0.45) | F2PRSS1F10PLG | |
| SCHEMBL14082058 | 0.81 | F2 (0.62) | F2PRSS1F10PLGPLAT | |
| SCHEMBL5862690 | 0.76 | F2 (0.52) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL13141174 | 0.76 | F2 (0.39) | F2PRSS1F10PLGPLAT | |
| SCHEMBL23793969 | 0.75 | F2 (0.75) | F2PRSS1F10PLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605371-B2 | Combination therapy for cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-04-21 | — | — | US | claimed |
| US-12521258-B2 | Anticoagulant compounds and methods and devices for their use | ELIXIR MEDICAL CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| WO-2025262269-A1 | MONITORING OF REVERSAL AGENTS FOR ANTICOAGULANTS | ENZYRE B.V. (NL) | 2025-12-26 | — | — | WO | claimed |
| US-20250177502-A1 | THROMBIN AND FIBRINOGEN AS TARGETS FOR ATOPIC DERMATITIS DIAGNOSIS AND TREATMENT | CHILDRENS HOSPITAL MED CT (US) | 2025-06-05 | — | — | US | claimed |
| WO-2025019850-A1 | COMPOSITIONS AND METHODS FOR REDUCING NANOPARTICLE-ASSOCIATED COAGULATION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-01-23 | — | — | WO | claimed |
| US-20240424175-A1 | ANTICOAGULANT COMPOUNDS COMPRISING CHELATING AGENTS AND CATIONIC ANTI-COAGULATION ENHANCERS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2024-12-26 | — | — | US | claimed |
| WO-2024238703-A1 | ANTICOAGULANT COMPOSITIONS COMPRISING ANTI-PLATELET AND ANTI-INFLAMMATORY DRUGS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2024-11-21 | — | — | WO | claimed |
| EP-4463185-A2 | THROMBIN AND FIBRINOGEN AS TARGETS FOR ATOPIC DERMATITIS DIAGNOSIS AND TREATMENT | Children's Hospital Medical Center (US) | 2024-11-20 | — | — | EP | claimed |
| US-20240277773-A1 | COMPOSITION AND PROCESS FOR AN INFILTRATION AND TRANSPORT MEDIUM FOR ADIPOSE TISSUE CELLS | UNIVERSITEIT GENT (BE) | 2024-08-22 | — | — | US | claimed |
| US-20240189495-A1 | METHODS OF PREPARING AN EXTRACORPOREAL CIRCUIT FOR ANTICOAGULATION | LOWELL THERAPEUTICS, LLC | 2024-06-13 | — | — | US | claimed |
| WO-2000041715-A1 | NEW DIALYSIS METHOD | ASTRAZENECA AB (SE) | 2000-07-20 | — | — | WO | claimed |
| WO-2000012043-A1 | IMPROVED STABILITY FOR INJECTION SOLUTIONS | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | claimed |
| EP-0942960-A1 | PROMOTION OF REGENERATION OF ORGANIZED TISSUES | Hansson, Hans-Arne (SE) | 1999-09-22 | — | — | EP | claimed |
| CN-1219965-A | Promoting regeneration of organotypic tissue | HANS ARNE HANSSON (SE) | 1999-06-16 | — | — | CN | claimed |
| CN-1213309-A | Control of healing process | HANSSON HANS ARNE (SE) | 1999-04-07 | — | — | CN | claimed |
| EP-0874634-A1 | CONTROL OF HEALING PROCESS | Hansson, Hans-Arne (SE) | 1998-11-04 | — | — | EP | claimed |
| WO-1998016252-A1 | NEW PHARMACEUTICAL PARENTERAL FORMULATION OF A THROMBIN INHIBITOR | ASTRA AKTIEBOLAG (SE) | 1998-04-23 | — | — | WO | claimed |
| WO-1997039770-A1 | NEW PHARMACEUTICAL FORMULATION OF A THROMBIN INHIBITOR FOR PARENTERAL USE | ASTRA AKTIEBOLAG (SE) | 1997-10-30 | — | — | WO | claimed |
| WO-1997037002-A1 | PROMOTION OF REGENERATION OF ORGANIZED TISSUES | HANSSON HANS ARNE (SE) | 1997-10-09 | — | — | WO | claimed |
| WO-1997025994-A1 | CONTROL OF HEALING PROCESS | HANSSON HANS ARNE (SE) | 1997-07-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605371-B2 | Combination therapy for cancer | BRAF, TFPI, HGFAC | F2 39/4885PRSS1 311/4885F10 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.